Back

Ablation outcome and post-interventional management of anticoagulation in patients with obesity or severe obesity and atrial fibrillation

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation in atrial fibrillation Oral Anticoagulation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Ms Rangine-Suhal Bares

Munich (Germany)

4 More presentations in this session

Presentation thumbnail
Impact of kidney function on cardiovascular outcome in patients with device-detected atrial fibrillation in NOAH-AFNET 6
Professor A. Goette (Paderborn, DE)
Abstract Slides Video
Presentation thumbnail
Outcomes after cavotricuspid isthmus ablation: predictors of new-onset atrial fibrillation and stroke according to anticoagulation strategy
Doctor J. Villoria Martin (Huelva, ES)
Abstract Slides Video
Presentation thumbnail
Distribution of apixaban plasma concentrations across prescribed dose groups for ischemic stroke prevention in atrial fibrillation
Associate Professor K. Lim (Busan, KR)
Abstract Slides Video
Presentation thumbnail
CHA2DS2-VASc score-based anticoagulation management after catheter ablation for atrial fibrillation: a post-hoc analysis of the ALONE-AF trial
Doctor Y. Lee (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulation in atrial fibrillation

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Presentation
Association of body mass index with arrhythmia progression and outcomes in patients with subclinical atrial fibrillation: insights from the ARTESiA trial
thumbnail
Congress Presentation
The effect of weight loss on atrial fibrillation freedom compared to catheter ablation: a sub-analysis of the PRAGUE-25 trial
thumbnail
Congress Presentation
Left-atrial function in relation to BMI in patients undergoing catheter ablation for atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources